Guillain–Barré syndrome and Fisher syndrome: Case definitions and guidelines for collection, analysis, and presentation of immunization safety data
about
Population Incidence of Guillain-Barré Syndrome: A Systematic Review and Meta-AnalysisGuillain–Barré and Miller Fisher syndromes—new diagnostic classificationGuillain–Barré syndrome: pathogenesis, diagnosis, treatment and prognosisIntravenous immunoglobulin for Guillain-Barré syndromeGuillain-Barré Syndrome and Healthcare Needs during Zika Virus Transmission, Puerto Rico, 2016Guillain-Barre syndrome complicating chikungunya virus infectionGuillain-Barré Syndrome, Influenza Vaccination, and Antecedent Respiratory and Gastrointestinal Infections: A Case-Centered Analysis in the Vaccine Safety Datalink, 2009-2011.Guillain-Barré syndrome surveillance during National Influenza Vaccination Campaign, New York, U.S.A., 2009.Guillain-Barré syndrome and adjuvanted pandemic influenza A (H1N1) 2009 vaccines: a multinational self-controlled case series in EuropePandemic A/H1N1 2009 influenza vaccination, preceding infections and clinical findings in UK children with Guillain-Barré syndrome.Risk of Guillain-Barré syndrome following pandemic influenza A(H1N1) 2009 vaccination in GermanyGuillain-Barré syndrome following the 2009 pandemic monovalent and seasonal trivalent influenza vaccination campaigns in Spain from 2009 to 2011: outcomes from active surveillance by a neurologist network, and records from a country-wide hospital diGuillain-Barre syndrome and adjuvanted pandemic influenza A (H1N1) 2009 vaccine: multinational case-control study in Europe[Guillain-Barré syndrome after exposure to influenza].A new animal model of spontaneous autoimmune peripheral polyneuropathy: implications for Guillain-Barré syndromeGuillain-Barré syndrome: natural history and prognostic factors: a retrospective review of 106 casesPost-licensure safety surveillance for human papillomavirus-16/18-AS04-adjuvanted vaccine: more than 4 years of experience.Deaths following vaccination: What does the evidence show?Adverse events following quadrivalent meningococcal CRM-conjugate vaccine (Menveo®) reported to the Vaccine Adverse Event Reporting system (VAERS), 2010-2015.Diagnosis of Guillain-Barré syndrome in children and validation of the Brighton criteriaA report of guillain-barré syndrome with myalgia and mild weaknessClinical Features of Post-Vaccination Guillain-Barré Syndrome (GBS) in Korea.Risk of bias and confounding of observational studies of Zika virus infection: A scoping review of research protocolsGuillain-Barre syndrome following quadrivalent human papillomavirus vaccination among vaccine-eligible individuals in the United States.Guillain-Barré syndrome incidence in a large United States cohort (2000-2009).The Pathogenesis of the Demyelinating Form of Guillain-Barre Syndrome (GBS): Proteo-peptidomic and Immunological Profiling of Physiological Fluids.Sural sparing pattern discriminates Guillain-Barré syndrome from its mimics.Adverse Events Following Measles, Mumps, and Rubella Vaccine in Adults Reported to the Vaccine Adverse Event Reporting System (VAERS), 2003-2013Hospital Admissions, Transfers and Costs of Guillain-Barré Syndrome.Post-Marketing Surveillance of Human Rabies Diploid Cell Vaccine (Imovax) in the Vaccine Adverse Event Reporting System (VAERS) in the United States, 1990‒2015.Guillain-Barré syndrome: clinical profile and management.Template protocol for clinical trials investigating vaccines--focus on safety elementsNeuroepidemiology and the epidemiology of viral infections of the nervous systemGuillain-Barré Syndrome in India: population-based validation of the Brighton criteria.The contribution of the vaccine adverse event text mining system to the classification of possible Guillain-Barré syndrome reports.Guillain-Barre syndrome as a paraneoplastic manifestation of disseminated squamous cell carcinomaRisk of Guillain-Barré syndrome after 2010-2011 influenza vaccination.Epidemiology of Guillain-Barré Syndrome in Aruba.Post-licensure surveillance of quadrivalent inactivated influenza (IIV4) vaccine in the United States, Vaccine Adverse Event Reporting System (VAERS), July 1, 2013-May 31, 2015Safety of MF59-adjuvanted influenza vaccination in the elderly: results of a comparative study of MF59-adjuvanted vaccine versus nonadjuvanted influenza vaccine in northern Italy.
P2860
Q22241939-2A4F0406-8BD4-4DD6-B6C8-5E935EE30394Q22251010-C366EFB3-C0A1-42C8-A4A1-AC0CA635E1C6Q22251013-CB2089FF-F623-4BB7-A9EF-A4CD1F38C040Q24193522-12F6C6CC-A417-4E40-AD10-684EE9D195F8Q28119750-A8228C61-652A-40D6-B88B-B57EA555548AQ28804145-D4C1DB4D-6E21-4598-BA40-B49358B1352EQ30351998-B7F684FD-E2DE-4413-83B9-393365E35368Q30356015-4ED67FFA-2600-418F-B042-CE3886C5EB3DQ30357675-6F8875E4-989B-4564-B009-F9BD71B3E8A2Q30359657-79E5EC55-4408-4A6B-B832-921C0FC7CB07Q30362413-480BAB69-5500-46DD-9E9A-15489B9FE1C0Q30388367-E7B1FF6F-68D0-4539-A90D-B363ADDCA287Q30404728-AB743EEF-A2EF-4927-80DE-E7D05E6EA4E9Q30415924-E6D15E89-6954-4138-AB42-ED2492DA7BE2Q30565519-A63236C8-B08A-4A31-B972-43B8F6B312FAQ31123673-937B5FCD-E288-4D9D-B21E-D0A08CEBF9E6Q33163984-AE6407D4-BDFB-4119-A479-C369144DC6D4Q33165769-37E34382-833C-40D2-A2AB-54B362739FB8Q33168344-8AF03120-8F95-4666-82B5-7D2766AB8007Q33627830-B3452CB6-F666-4E24-B928-C9C7DCC95339Q33757198-F639D614-ABCB-4569-9192-965C59C84515Q33770375-707C9E1A-19FE-45DE-9B9F-2E08C142375BQ33883729-DDEB02C9-F18D-474B-AA87-49BCE9BA501CQ34271547-28B05EC3-C536-4670-AC5A-E459103D826BQ34640979-6634CF86-5F0B-44C6-957B-2A5FBDB137DAQ34677183-B22BE519-2DA3-48EC-B8DF-DC2FB250CD26Q35606247-BFE5DFF7-839E-404F-8FED-A56C6809BE43Q35661817-B98CA1AE-2B38-4BE2-9FAF-F73E556A2603Q35918443-C99DBA69-1379-48EA-9001-CBBE456E2E99Q36075411-2DDC908C-2D86-4091-A71A-2920E4F3533AQ36076638-EB4CD081-0A79-469E-92CC-DF7A580EA3E3Q36100736-02D7D369-D475-4A24-AC52-205C34EE748AQ36518544-CC3FDCD1-1F1F-450A-BB62-C8A2FEEE6458Q36800813-78772109-52C6-4B40-9FE7-DCE70E5F3DBBQ36817854-0447DCC8-605D-4221-B513-05B09D9CECD9Q36894028-6442F80D-D251-4861-9356-F3710755173DQ36902462-C359C195-2D2A-4AF0-8EA4-B60F7F0A9AB4Q36958561-707561C1-B862-4F87-96A4-6AFB4656BC52Q37027049-52CFF355-3CDC-44F1-978C-2668F5B19D41Q37197620-99DB44D6-1E8D-4557-9A8F-806987874B0B
P2860
Guillain–Barré syndrome and Fisher syndrome: Case definitions and guidelines for collection, analysis, and presentation of immunization safety data
description
2011 nî lūn-bûn
@nan
2011 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Guillain–Barré syndrome and Fi ...... on of immunization safety data
@ast
Guillain–Barré syndrome and Fi ...... on of immunization safety data
@en
Guillain–Barré syndrome and Fi ...... on of immunization safety data
@en-gb
Guillain–Barré syndrome and Fi ...... on of immunization safety data
@nl
type
label
Guillain–Barré syndrome and Fi ...... on of immunization safety data
@ast
Guillain–Barré syndrome and Fi ...... on of immunization safety data
@en
Guillain–Barré syndrome and Fi ...... on of immunization safety data
@en-gb
Guillain–Barré syndrome and Fi ...... on of immunization safety data
@nl
altLabel
Guillain-Barré syndrome and Fi ...... on of immunization safety data
@en
prefLabel
Guillain–Barré syndrome and Fi ...... on of immunization safety data
@ast
Guillain–Barré syndrome and Fi ...... on of immunization safety data
@en
Guillain–Barré syndrome and Fi ...... on of immunization safety data
@en-gb
Guillain–Barré syndrome and Fi ...... on of immunization safety data
@nl
P2093
P50
P3181
P1433
P1476
Guillain–Barré syndrome and Fi ...... on of immunization safety data
@en
P2093
Anthony Amato
Barbara J. Law
Dale R. Burwen
David R. Cornblath
Helena C. Maltezou
James Oleske
Jan Cleerbout
Jane Gidudu
Najwa Khuri-Bulos
Nandini Bakshi
P304
P3181
P356
10.1016/J.VACCINE.2010.06.003
P407
P577
2011-01-01T00:00:00Z